.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Merck
Colorcon
Accenture
US Department of Justice
Moodys
US Army
Cantor Fitzgerald
UBS
Fuji

Generated: December 14, 2017

DrugPatentWatch Database Preview

Avobenzone; ecamsule; octocrylene - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for avobenzone; ecamsule; octocrylene and what is the scope of avobenzone; ecamsule; octocrylene patent protection?

Avobenzone; ecamsule; octocrylene
is the generic ingredient in four branded drugs marketed by Loreal Usa and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for avobenzone; ecamsule; octocrylene. One supplier is listed for this compound.

Summary for avobenzone; ecamsule; octocrylene

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Loreal UsaANTHELIOS 20avobenzone; ecamsule; octocrylene; titanium dioxideCREAM;TOPICAL021471-001Oct 5, 2006OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Loreal UsaANTHELIOS 40avobenzone; ecamsule; octocrylene; titanium dioxideCREAM;TOPICAL022009-001Mar 31, 2008OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Loreal UsaANTHELIOS 40avobenzone; ecamsule; octocrylene; titanium dioxideCREAM;TOPICAL022009-002Oct 29, 2009OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Loreal UsaCAPITAL SOLEIL 15avobenzone; ecamsule; octocryleneCREAM;TOPICAL021501-001Oct 2, 2006OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Loreal UsaANTHELIOS SXavobenzone; ecamsule; octocryleneCREAM;TOPICAL021502-001Jul 21, 2006OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: avobenzone; ecamsule; octocrylene

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Loreal UsaANTHELIOS SXavobenzone; ecamsule; octocryleneCREAM;TOPICAL021502-001Jul 21, 2006► Subscribe► Subscribe
Loreal UsaANTHELIOS SXavobenzone; ecamsule; octocryleneCREAM;TOPICAL021502-001Jul 21, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Fuji
Cipla
Healthtrust
Teva
Argus Health
Novartis
Cerilliant
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot